These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 24952901)

  • 21. Tumor heterogeneity and implications for clinical practice.
    Chu E
    Oncology (Williston Park); 2014 Sep; 28(9):726, 741. PubMed ID: 25224470
    [No Abstract]   [Full Text] [Related]  

  • 22. TCPA v3.0: An Integrative Platform to Explore the Pan-Cancer Analysis of Functional Proteomic Data.
    Chen MM; Li J; Wang Y; Akbani R; Lu Y; Mills GB; Liang H
    Mol Cell Proteomics; 2019 Aug; 18(8 suppl 1):S15-S25. PubMed ID: 31201206
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor heterogeneity is fundamental to the tumor ecosystem.
    Heppner GH; Shekhar M
    Oncology (Williston Park); 2014 Sep; 28(9):780-1. PubMed ID: 25224476
    [No Abstract]   [Full Text] [Related]  

  • 24. The impact of DNA methylation on the cancer proteome.
    Magzoub MM; Prunello M; Brennan K; Gevaert O
    PLoS Comput Biol; 2019 Jul; 15(7):e1007245. PubMed ID: 31356589
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Associating somatic mutations to clinical outcomes: a pan-cancer study of survival time.
    Little P; Lin DY; Sun W
    Genome Med; 2019 May; 11(1):37. PubMed ID: 31138328
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic value of cross-omics screening for kidney clear cell renal cancer survival.
    Dimitrieva S; Schlapbach R; Rehrauer H
    Biol Direct; 2016 Dec; 11(1):68. PubMed ID: 27993167
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A systematic comparison of copy number alterations in four types of female cancer.
    Kaveh F; Baumbusch LO; Nebdal D; Børresen-Dale AL; Lingjærde OC; Edvardsen H; Kristensen VN; Solvang HK
    BMC Cancer; 2016 Nov; 16(1):913. PubMed ID: 27876019
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumor heterogeneity: the Lernaean hydra of oncology?
    Janiszewska M; Beca F; Polyak K
    Oncology (Williston Park); 2014 Sep; 28(9):781-2, 784. PubMed ID: 25224477
    [No Abstract]   [Full Text] [Related]  

  • 29. Database of genomic biomarkers for cancer drugs and clinical targetability in solid tumors.
    Dienstmann R; Jang IS; Bot B; Friend S; Guinney J
    Cancer Discov; 2015 Feb; 5(2):118-23. PubMed ID: 25656898
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Can MGMT promoter methylation status be used as a prognostic and predictive marker for glioblastoma multiforme at the present time? A word of caution.
    Fietkau R; Putz F; Lahmer G; Semrau S; Buslei R
    Strahlenther Onkol; 2013 Dec; 189(12):993-5. PubMed ID: 24177536
    [No Abstract]   [Full Text] [Related]  

  • 31. Integrated genomic analysis for prediction of survival for patients with liver cancer using The Cancer Genome Atlas.
    Song YZ; Li X; Li W; Wang Z; Li K; Xie FL; Zhang F
    World J Gastroenterol; 2018 Jul; 24(28):3145-3154. PubMed ID: 30065560
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increased methylation variation in epigenetic domains across cancer types.
    Hansen KD; Timp W; Bravo HC; Sabunciyan S; Langmead B; McDonald OG; Wen B; Wu H; Liu Y; Diep D; Briem E; Zhang K; Irizarry RA; Feinberg AP
    Nat Genet; 2011 Jun; 43(8):768-75. PubMed ID: 21706001
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Integrative data mining and meta-analysis to investigate the prognostic role of microRNA-200 family in various human malignant neoplasms: A consideration on heterogeneity.
    Yuan L; Bing Z; Yan P; Li R; Wang C; Sun X; Yang J; Shi X; Zhang Y; Yang K
    Gene; 2019 Oct; 716():144025. PubMed ID: 31394177
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.
    Zehir A; Benayed R; Shah RH; Syed A; Middha S; Kim HR; Srinivasan P; Gao J; Chakravarty D; Devlin SM; Hellmann MD; Barron DA; Schram AM; Hameed M; Dogan S; Ross DS; Hechtman JF; DeLair DF; Yao J; Mandelker DL; Cheng DT; Chandramohan R; Mohanty AS; Ptashkin RN; Jayakumaran G; Prasad M; Syed MH; Rema AB; Liu ZY; Nafa K; Borsu L; Sadowska J; Casanova J; Bacares R; Kiecka IJ; Razumova A; Son JB; Stewart L; Baldi T; Mullaney KA; Al-Ahmadie H; Vakiani E; Abeshouse AA; Penson AV; Jonsson P; Camacho N; Chang MT; Won HH; Gross BE; Kundra R; Heins ZJ; Chen HW; Phillips S; Zhang H; Wang J; Ochoa A; Wills J; Eubank M; Thomas SB; Gardos SM; Reales DN; Galle J; Durany R; Cambria R; Abida W; Cercek A; Feldman DR; Gounder MM; Hakimi AA; Harding JJ; Iyer G; Janjigian YY; Jordan EJ; Kelly CM; Lowery MA; Morris LGT; Omuro AM; Raj N; Razavi P; Shoushtari AN; Shukla N; Soumerai TE; Varghese AM; Yaeger R; Coleman J; Bochner B; Riely GJ; Saltz LB; Scher HI; Sabbatini PJ; Robson ME; Klimstra DS; Taylor BS; Baselga J; Schultz N; Hyman DM; Arcila ME; Solit DB; Ladanyi M; Berger MF
    Nat Med; 2017 Jun; 23(6):703-713. PubMed ID: 28481359
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Integrative genomic analyses reveal clinically relevant long noncoding RNAs in human cancer.
    Du Z; Fei T; Verhaak RG; Su Z; Zhang Y; Brown M; Chen Y; Liu XS
    Nat Struct Mol Biol; 2013 Jul; 20(7):908-13. PubMed ID: 23728290
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Breast and prostate cancers harbor common somatic copy number alterations that consistently differ by race and are associated with survival.
    Chen Y; Sadasivan SM; She R; Datta I; Taneja K; Chitale D; Gupta N; Davis MB; Newman LA; Rogers CG; Paris PL; Li J; Rybicki BA; Levin AM
    BMC Med Genomics; 2020 Aug; 13(1):116. PubMed ID: 32819446
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of multiple DNA copy number alterations including frequent 8p11.22 amplification in conjunctival squamous cell carcinoma.
    Asnaghi L; Alkatan H; Mahale A; Othman M; Alwadani S; Al-Hussain H; Jastaneiah S; Yu W; Maktabi A; Edward DP; Eberhart CG
    Invest Ophthalmol Vis Sci; 2014 Dec; 55(12):8604-13. PubMed ID: 25491297
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Integration of somatic mutation, expression and functional data reveals potential driver genes predictive of breast cancer survival.
    Suo C; Hrydziuszko O; Lee D; Pramana S; Saputra D; Joshi H; Calza S; Pawitan Y
    Bioinformatics; 2015 Aug; 31(16):2607-13. PubMed ID: 25810432
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predicting censored survival data based on the interactions between meta-dimensional omics data in breast cancer.
    Kim D; Li R; Dudek SM; Ritchie MD
    J Biomed Inform; 2015 Aug; 56():220-8. PubMed ID: 26048077
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correlating bladder cancer risk genes with their targeting microRNAs using MMiRNA-Tar.
    Liu Y; Baker S; Jiang H; Stuart G; Bai Y
    Genomics Proteomics Bioinformatics; 2015 Jun; 13(3):177-82. PubMed ID: 26169799
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.